Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Devlin

Showing results (741-750 of 803) with videos related to

Pageof 81
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34<sup>+</sup> Selected and Unmodified Hematopoietic Stem Cell TransplantationRoni Tamari, Betul Oran, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2017
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Satyajit Kosuri, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 5, 2015
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous LeukemiaDoris M Ponce, Patrick Hilden, Sean M Devlin, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Bone Marrow Transplantation|February 1, 2025
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphomaMagdalena Corona, Andrew Ip, Samantha Brown, et al.
Leukemia|June 20, 2020
Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulinIoannis Politikos, Sean M Devlin, Maria E Arcila, et al.
Pageof 81

Showing results (741-750 of 803) with videos related to

Sort By:
Pageof 81
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34<sup>+</sup> Selected and Unmodified Hematopoietic Stem Cell TransplantationRoni Tamari, Betul Oran, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2017
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Satyajit Kosuri, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 5, 2015
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous LeukemiaDoris M Ponce, Patrick Hilden, Sean M Devlin, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Bone Marrow Transplantation|February 1, 2025
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphomaMagdalena Corona, Andrew Ip, Samantha Brown, et al.
Leukemia|June 20, 2020
Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulinIoannis Politikos, Sean M Devlin, Maria E Arcila, et al.
Pageof 81